SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001593968-24-000842
Filing Date
2024-06-11
Accepted
2024-06-11 16:10:19
Documents
1
Period of Report
2024-06-05

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_01.html 3  
1 PRIMARY DOCUMENT primary_01.xml 3 3613
  Complete submission text file 0001593968-24-000842.txt   5056
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 7000 SHORELINE COURT SUITE 201 SOUTH SAN FRANCISCO CA 94080
Business Address
Yoshiyama Annie (Reporting) CIK: 0001835208 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38693 | Film No.: 241035853